RYTM
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Article Summary
HOLD- Rhythm Pharmaceuticals Inc. (Nasdaq: RYTM) announced that it will host a live conference call and webcast at 8:00 a.m.
- ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update.
- Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, and the conference call is expected to focus on financial performance and operational highlights.
- While not required, it is recommended that participants join the call ten minutes prior to scheduled start, and a recording of the call will also be available under Events and Presentations in Rhythm Pharmaceuticals's investor relations section.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 58.7% | 25% | 100.0 ptsExceptional (58.7%) - Hypergrowth |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 30.8% | 20% | 85.0 ptsLarge Upside (30.8%) - Target: $139.73 vs Current: $106.85 |
| Gross Margin % ? | 89.3% | 15% | 100.0 ptsExceptional (89.3%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -12.6% | 15% | 40.0 ptsMild Pullback (-12.6%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About RYTM
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
- The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
- It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency.
- The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity.
- The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
- Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.